Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980102 | 0.87 | KDM4E (0.53) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL23675135 | 0.85 | NAMPT (0.50) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL15558786 | 0.83 | CTNNB1 (0.68) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL29902860 | 0.81 | NAMPT (0.56) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL29902873 | 0.81 | NAMPT (0.56) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL7399036 | 0.80 | POLB (0.70) | NAMPTKDM4EHTTRAB9ASMN1; SMN2 | |
| SCHEMBL496967 | 0.80 | IP6K1 (0.65) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL3154557 | 0.79 | P2RY14 (0.53) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL26686922 | 0.79 | PRKCI (0.53) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL31226001 | 0.78 | ABCC4 (0.49) | NAMPTALDH1A1KDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | disclosed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3305297-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITION OF HSP90 | Sloan-Kettering Institute for Cancer Research (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-12-25 | — | — | US | disclosed |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-03 | — | — | US | disclosed |
| US-7186720-B2 | Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same | SANOFI-AVENTIS (FR) | 2007-03-06 | — | — | US | disclosed |
| US-20040138264-A1 | Tetrahydropyridly-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | NAMPT 116/4885ALDH1A1 1851/4885KDM4E 4392/4885 |
| US-20040138264-A1 | Tetrahydropyridly-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same | CYP2F1, CYP11B1, CYP11B2 | NAMPT 773/4885ALDH1A1 1579/4885KDM4E 2820/4885 |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | NAMPT 116/4885ALDH1A1 1851/4885KDM4E 4392/4885 |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | NAMPT 116/4885ALDH1A1 1851/4885KDM4E 4392/4885 |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | NAMPT 296/4885ALDH1A1 1998/4885KDM4E 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.